{"id":"cisplatin-as-radiosensitizer","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Ototoxicity"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"25-50","effect":"Myelosuppression"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"15-30","effect":"Electrolyte abnormalities (hypomagnesemia, hypokalemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin is a platinum-based chemotherapy agent that binds to DNA and creates interstrand and intrastrand crosslinks. When combined with radiation therapy, these DNA lesions become more difficult for cells to repair, significantly enhancing radiation-induced cell death. This synergistic effect makes cisplatin an effective radiosensitizing agent in concurrent chemoradiation regimens.","oneSentence":"Cisplatin acts as a radiosensitizer by forming DNA adducts that enhance the cytotoxic effects of ionizing radiation, making cancer cells more susceptible to radiation-induced damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:03.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Concurrent chemoradiation for locally advanced cancers (head and neck, cervical, lung, esophageal)"}]},"trialDetails":[{"nctId":"NCT07022483","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-09-30","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":3},{"nctId":"NCT01880359","phase":"PHASE3","title":"AF CRT +/- Nimorazole in HNSCC","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2014-07-25","conditions":"Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers","enrollment":640},{"nctId":"NCT00428194","phase":"PHASE1","title":"Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-01","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT00077051","phase":"PHASE1","title":"Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT00410826","phase":"PHASE2","title":"Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-06","conditions":"Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","enrollment":204},{"nctId":"NCT00660270","phase":"PHASE2","title":"Chemotherapy and Radiation Following Pancreatic Surgery","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2002-05","conditions":"Pancreatic Cancer","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Platinol®","Platinol®-AQ"],"phase":"phase_3","status":"active","brandName":"Cisplatin (as radiosensitizer)","genericName":"Cisplatin (as radiosensitizer)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin acts as a radiosensitizer by forming DNA adducts that enhance the cytotoxic effects of ionizing radiation, making cancer cells more susceptible to radiation-induced damage. Used for Concurrent chemoradiation for locally advanced cancers (head and neck, cervical, lung, esophageal).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}